Kymera Therapeutics, Inc.
NASDAQ:KYMRBiotechnology
Healthcare
$119.39 +1.67%
+$1.50 today
- Market cap
- $10.19B
- Beta
- 2.03
- P/E (TTM)
- -28.3
- EPS (TTM)
- -$3.23
52W Low $36.65High $103.00
Volume 0.72M
Average 0.58M
Balance Sheet
Inspect the capital base behind the business.
Assets
$1.74B
FY 2025 · Annual
+78.2% YoYLiabilities
$163.15M
FY 2025 · Annual
+14.6% YoYEquity
$1.58B
FY 2025 · Annual
+89.0% YoYBalance Sheet
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 47.98M | 68.4M | 109.97M | 120.26M | 357.01M |
| Short-term Investments | 394.44M | 338.77M | 264.92M | 368.49M | 491.27M |
| Net Receivables | 135K | 2.54M | 18.76M | 947K | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 9.71M | 11.67M | 20.58M | 22.94M |
| Total Current Assets | 451.27M | 419.42M | 405.32M | 510.27M | 871.21M |
| Property, Plant & Equipment (Net) | 21.31M | 22.24M | 101.08M | 97.86M | 85.53M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 125.19M | 152.33M | 61.43M | 362.16M | 776.96M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 8.14M | 9.15M | 7.93M | 7.74M | 9.11M |
| Total Non-current Assets | 154.63M | 183.72M | 170.44M | 467.77M | 871.6M |
| Total Assets | 605.91M | 603.13M | 575.76M | 978.04M | 1.74B |
| Account Payables | 4.01M | 4.34M | 7.08M | 5.99M | 4.01M |
| Short-term Debt | 0 | 0 | 0 | 0 | 13.76M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 61.74M | 35.26M | 37.88M | 13.58M | 22.93M |
| Other Current Liabilities | 228K | 303K | 23.16M | 223K | 24.21M |
| Total Current Liabilities | 92.54M | 71.34M | 85.69M | 67.77M | 83.21M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 39.3M | 28M | 16.77M | 0 | 11.44M |
| Other Non-current Liabilities | 66K | 248K | 0 | 0 | 0 |
| Total Non-current Liabilities | 53.73M | 41.64M | 95.1M | 74.65M | 79.94M |
| Total Liabilities | 146.27M | 112.98M | 180.79M | 142.42M | 163.15M |
| Common Stock | 5K | 6K | 6K | 7K | 8K |
| Retained Earnings | (228.98M) | (383.79M) | (530.75M) | (754.61M) | (1.07B) |
| Accumulated OCI | (660K) | (4.95M) | (552K) | (1.49M) | 1.8M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 459.64M | 490.15M | 394.97M | 835.62M | 1.58B |
| Total Debt | 17.96M | 17.34M | 84.67M | 87.76M | 82.25M |
| Net Debt | (30.01M) | (51.06M) | (25.29M) | (32.5M) | (274.76M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $124.5M |
| Short-term Investments | $566.5M |
| Receivables | $20.0M |
| Inventory | -$5.8M |
| Other Current | $32.1M |
| Total Current Assets | $737.3M |
| PP&E (Net) | $81.1M |
| Long-term Investments | $813.9M |
| Other Non-current | $7.0M |
| Total Non-current Assets | $902.0M |
| Total Assets | $1.6B |
Analysis
Selected assets total $1.6B for Latest. The largest visible component is Long-term Investments at $813.9M, about 49.5% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Oct 29, 2026 | |
| 10-Q | Quarterly report | Oct 29, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 27, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 1, 2026 | |
| SC 13G/A | SC 13G/A filing | Sep 8, 2026 |
How much cash does KYMR have?
Kymera Therapeutics, Inc. (KYMR) reported $357.01M in cash and equivalents in fiscal 2025.
How much debt does KYMR carry?
Kymera Therapeutics, Inc. (KYMR) reported $82.25M of total debt, with net debt of -$274.76M.
Continue the stock analysis
Jump to another research area for this company.